• The risk of bleeding influences the duration of anticoagulation (AC) after venous thromboembolism.
Essentials
• The risk of bleeding influences the duration of anticoagulation (AC) after venous thromboembolism.
• We assessed the ACCP bleeding risk score in an inception-cohort of patients receiving AC.
• 53% were categorized at high-risk, but their bleeding rate was low during long-term AC.
• ACCP score had low predictive value for bleeding.
Summary. Background: The American College of Chest Physicians (ACCP) guideline proposes a score to decide on extended anticoagulation after an unprovoked venous thromboembolism (VTE). Methods: We investigated the ACCP score to predict bleeding risk in an inception cohort of 2263 patients on long-term anticoagulation (1522 treated with vitamin K antagonists [VKAs] and the remaining with direct oral anticoagulants [DOACs] ) belonging to the Italian START2 Register. Results: More than half the patients were categorized as high risk; nevertheless, a higher proportion received anticoagulation for > 1 year compared with those in the low-risk category. For 3130 years (median 12 [interquartile range 6, 24] months), 48 bleeding outcomes occurred (1.53%/year) in the cohort (1.7%/year and 0.95%/year in high-and low-risk categories, respectively). The c-statistic of the ACCP score was 0.55 (0.48-0.63), 0.50 (0.42-0.58) and 0.56 (0.48-0.64) in low-, moderate-and high-risk categories, respectively. The bleeding incidence was higher during the first 90 days of treatment (3.0%/year) than afterwards (1.2%/year; relative risk (RR), 2.5 [1.3-4.7] ), and similar among the three categories. The bleeding rate was not different during the initial 3 months of treatment in patients receiving VKAs or DOACs; it was, however, lower in the latter patients in the subsequent period (0.5%/year vs. 1.4%/year, respectively). Conclusion: The bleeding rate during extended treatment was rather low in our patients. ACCP score had insufficiently predictive value for bleeding and cannot be used to guide decisions on extended treatment. New prediction tools for bleeding risk during anticoagulant treatments (including DOACs) are required.
Introduction
After acute venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and/or pulmonary embolism (PE), urgent and adequate anticoagulant therapy is necessary to prevent extension, potentially fatal PE and early recurrence. Although at least 3 months of anticoagulation are needed to treat an acute VTE episode adequately [1, 2] , extended treatment is often recommended to prevent delayed recurrences. Prospective studies have conclusively shown that the cumulative incidence of recurrent VTE may reach 18%, 25% and even 30% after 2, 5 and 8 years, respectively [1] . Anticoagulation, with either vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), is highly protective against the risk of recurrence but is associated with a not negligible risk of bleeding. Two types of factors should therefore be taken into account when deciding the duration of anticoagulation in a single patient after a VTE event: (i) the risk of recurrent VTE, which is not the same for all patients and all the events; and (ii) the risk of bleeding if anticoagulation is extended. The decision on whether to stop anticoagulation after the first 3-6 months from the acute event or to continue it indefinitely (with a periodical reassessment of the patient's condition) will come from the balance between these two risks. Patients with an unprovoked VTE event have a higher risk of recurrences than those whose event is associated with a triggering and removable risk factor [2] , and for them, extended anticoagulant therapy is suggested, provided they do not have a high risk of bleeding [3] . The estimate of the individual risk of bleeding during anticoagulation is, however, not an easy task, especially in VTE patients, because in most cases their clinical history is free from bleeding events and clear pro-hemorrhagic conditions are very often absent.
Several clinical prediction tools for major bleeding in VTE patients have been proposed to help clinicians estimate the individual risk; some of them were limited to the risk during the acute phase of treatment [4] and others to long-term therapy [5] [6] [7] [8] . The American College of Chest Physicians (ACCP) clinical practice guideline [3] proposes a score that can be used to categorize patients into low, moderate or high risk of bleeding, and recommends against extended anticoagulation in patients with an unprovoked VTE who are classified at high risk of bleeding, whereas the extended treatment is suggested for those who are at low or moderate risk.
The aim of this study was to investigate the ability of the ACCP score to predict the risk of bleeding in an inception cohort of patients belonging to an Italian Register (START2), who had long-term anticoagulation. The ACCP score, which has not been validated as yet, was proposed to address the bleeding risk in patients treated with VKAs. In this study, we also included patients treated with DOACs, to assess how the score works separately for patients receiving VKAs or DOACs.
Materials and methods
The ACCP score
To predict the risk of bleeding during anticoagulation in VTE patients the ACCP clinical practice guideline [3] proposes a score that is based on the following risk factors for bleeding: age 66-75 years, age > 75 years, previous bleeding (major bleeding [MB] in the history), cancer (active), metastatic cancer, renal failure (CrCl < 30-60 mL min À1 ), liver failure (reported in the history), thrombocytopenia (< 100 000), previous stroke/transient ischemic attack (TIA), diabetes, anemia (Hb < 10), antiplatelet therapy, poor anticoagulant control (time spent in the therapeutic range < 60%), comorbidity, recent surgery (within 3 months from index event), frequent falls (≥ 2 in the last year), alcohol abuse (reported in the history) and non-steroidal anti-inflammatory drugs. According to the score, a patient's risk of major bleeding when on anticoagulant therapy is categorized as low (no bleeding risk factors; 0.8% annualized risk), moderate (one bleeding risk factor; 1.6%) or high (two or more bleeding risk factors; ≥ 6.5%).
Study population
All the anticoagulated patients who were registered in the START2 Register with the clinical indication of a first DVT episode of the lower limb and/or PE were included in the present study. The START2 Register is an observational, multicenter, dynamic cohort study that enrolled adults (aged at least 18 years) who started anticoagulation therapy, whatever the drug and dosage used [9] . The main aim of the START2 Register is to collect data on the incidence of adverse events in patients taking anticoagulant drugs. The Register was first authorized by the Ethical Institution Committee of the coordinating center (Azienda Ospedaliero-Universitaria, Policlinico S. Orsola-Malpighi, Bologna, Italy) in October 2011 (N = 142/2010/0/0ss") (NCT02219984), and then by the local institution review boards of all participating centers. The investigators and centers that participated in the START2 Register and contributed to the present study are listed in the Data S1. Patients aged 18 years or more are eligible for the register if they have been receiving anticoagulation therapy for no more than 30 days, have an expected follow-up of at least 12 months (even if anticoagulation is stopped before that period) and are not enrolled in phase II or III clinical studies. Participating centers are required to enroll their patients consecutively, without any exclusion criteria other than life expectancy or geographical inaccessibility. Definition of the time frame for enrolment (e.g. 1 week every month, or the first month of the year) is left to each participant's discretion, as long as it provides a random enrolment of patients. Patients are enrolled only after giving their informed consent. The correctness and completeness of the data collected anonymously in the central electronic database are checked by a trained and dedicated monitor of the study, who also solicits participating centers to contact, for the purpose of this study, patients lost to follow-up by a telephone call or through their general practitioner. The study was carried out and is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies [10] .
Data collection
Baseline data collection. Baseline characteristics of patients included in the present study were recorded in structured web-based case report forms (CRFs). The collected information included: demographic information, body weight, routine laboratory data, past medical history (hypertension, diabetes mellitus, heart failure, coronary artery disease, peripheral artery disease, atrial fibrillation, previous stroke or transient ischemic attack or systemic embolism, chronic pulmonary disease, gastrointestinal disease, thyroid disease, previous clinically relevant bleeding, malignancy, renal and liver function, and alcohol abuse), the therapeutic range expected in cases of treatment with a VKA, concomitant medications (antiplatelet drugs, corticosteroids or non-steroidal antiinflammatory drugs), characteristics of the VTE index event and presence of risk factors. VTE events were considered unprovoked, in line with the definition by Kearon et al. [2] , if they were not temporally associated with a major risk factor within 3 months of diagnosis (lower limb fracture, being in a cast or not weight bearing for ≥ 3 days, being bed-bound for 3 days because of acute illness, or surgery with general or spinal anesthesia), with a minor risk factor within 2 months of diagnosis (pregnancy, puerperium or leg trauma with limping for ≥ 3 days) or active cancer within 2 years of diagnosis. Serum creatinine levels were measured by local hospital laboratories, and creatinine clearance (CrCl) was calculated by the Cockcroft-Gault formula [11] . Renal failure was defined according to National Kidney Foundation stratification [12] .
Inclusion and follow-up data. As for all patients included in the START2 Register, participating centers are required to connect to the central electronic database, which is accessible on the web and protected by means of individual passwords for each participating center, and send information on baseline characteristics of included VTE patients and on their follow-up at least quarterly. Follow-up started from inclusion of the patients in the register and terminated in July 2017. For the scope of the present analysis, follow-up was considered from inclusion of patients until the interruption of anticoagulant treatment, or occurrence of major bleeding or thrombotic complications, whichever came first, or until July 2017. During follow-up detailed clinical reports of any relevant clinical outcome occurring in enrolled patients were collected. For patients on VKAs, all the international normalized ratio (INR) results were collected and time spent in the therapeutic range (TTR, computed according to the Roosendaal's method [13] ) was calculated.
Even though the ACCP score was aimed at assessing the risk of major bleeding (MB), the relevant clinical outcome for the present study was the composite of MB and clinically relevant non-major bleeding (CRNMB) events that occurred during anticoagulant treatment and up to 3 days after treatment discontinuation. The decision to include also CRNMB aimed to give more useful information to clinicians on the bleeding risk of extended anticoagulation because currently the potential risk of not only MB but also of CRNMB is usually taken into consideration when deciding on extending anticoagulant treatment or not. All documented bleeding events were reviewed centrally by an independent committee blinded to patients' characteristics and to other variables. MB was defined according to the International Society on Thrombosis and Haemostasis criteria [14] ) as: fatal, symptomatic in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, intramuscular with compartment syndrome, pericardial), or causing a fall in the hemoglobin level of at least 2 g/dl or leading to transfusion of at least two units of whole blood or red cells. CRNMB was defined as any overt bleeding requiring a medical intervention (hospitalization, surgery or interventional procedure, further diagnostic imaging, laboratory test or specialist evaluation) and/or treatment discontinuation, and not meeting any of the criteria for major bleeding [15] . For the scope of this study the follow-up of patients was censored at the moment of MB or CRNMB occurrence.
Statistical analysis
Based on previous data [16] , we assumed that about half of the cohort had at least two risk factors, thus potentially being considered as at high risk of bleeding. Because the risk of major bleeding was reported to be up to 8-fold higher in high-risk patients [3] , a sample of 2000 patients would provide sufficient power (80%) to test the hypothesis that high-risk patients have an at least 2.4-fold increased risk of major bleeding than patients considered as low risk.
Continuous variables are expressed as median with interquartile range (IQR) or as mean plus or minus standard deviation (SD). Categorical variables are expressed as frequencies and percentages. The number of bleeding events was expressed as percentage (with 95% confidence intervals [CIs]) and incidence rate, calculated as the number of events per 100 patient-years of observation. Coxregression and time-dependent c-statistics were used to explore the association between the proposed ACCP score (or individual variables concurring with it) and bleeding events. All variables found to be significant at univariate analysis were subsequently entered into a multivariate analysis to identify the most relevant risk factors for the outcome.
A calibration plot was drawn plotting the deciles of the predicted probabilities, calculated with Cox regression model, vs. the observed proportions of bleeding in each decile [17] . The SPSS software for Windows, version 22 (SPSS Inc., College Station, Texas, USA) and Stata, version 11 statistical software package (Stata Corp.) were used for data processing.
Results
The study included 2263 patients enrolled in the START2 Register as of July 2017 because they were started on anticoagulant treatment after the occurrence of DVT of the lower limb and/or PE; a small number (n = 49) of the patients were treated for recurrent superficial vein thrombosis, a potential indication for extended anticoagulation according to the Italian Federation of Anticoagulation Clinics, and they were also included in the study. The baseline characteristics of the patients are shown in Table 1 . Almost one-third of the entire population was aged > 75 years (29.3%). The index event was unprovoked in nearly two-thirds of cases (68.2%) and 67.3% of patients received VKAs as anticoagulant drugs; the remaining received one of the DOACs available at the moment of patient inclusion in the Register and reimbursed by the Italian national health system. Among the patients treated with a DOAC, 11.7% received the lower dose indicated by each drug company.
During the entire period of follow-up (3130 years; median follow-up 12 months [IQR 6, 24]), 48 bleeding outcomes were recorded in the cohort (2.2%; 1.53%/year); 28 were MB (0.9%/year) and 20 CRNMB (0.6%/year).
Patients
Bleeding was significantly more frequent in women than in men (2.2%/year vs. 0.9%/year, RR 2.5 [95% CI 1.2-5.1]). The prevalence of each risk factor included in the ACCP score in the study population is shown in Table 2 , together with the number of bleeding events that occurred in the patients with the risk factor and the corresponding hazard ratio (HR) compared with the events happening in patients without the factor. At multivariate analysis, a positive HR was detected for age 66-75 years, previous major bleeding in the history and poor anticoagulant control. Table 3 shows the distribution of the patient characteristics in the three categories of risk proposed by the ACCP score [3] . The absence of any risk factor (low-risk category) was recorded in 24.0% of the whole study cohort, whereas ≥ 2 factors (high-risk category) were detected in 52.9% of patients. More patients within the high-risk class were treated with anticoagulation for > 1 year in comparison with those in the low-risk class (P = 0.0001). Significantly more patients died during follow-up in the high-risk class (9.8%) than in the other categories (0.4% in the low-or moderate-risk groups; P = 0.0001), and none of the deaths were related to bleeding. The distribution among the three categories was similar in patients whose index event was provoked or unprovoked, and in patients treated with DOACs, but significantly more patients in the high-risk category were treated with VKAs.
Patients in the high-risk category experienced more bleeding events than those in the low-risk category (31 events, 1.7%/year vs. 6 events, 0.95%/year, respectively, P = 0.05), but the difference was no longer significant when the high-risk group was compared with the low and moderate-risk categories combined (Table 4 , Fig. 1 ). The discriminative capacity of the proposed ACCP score (cstatistics) was 0.55 (0.48-0.63) in the low-risk, 0.50 (0.42-0.58) in the moderate-risk and 0.56 (0.48-0.64) in the high-risk category. The rate of bleeding events in the whole study population was higher during the first 90 days of treatment (3.0%/year) than in the subsequent period (1.2%/year; RR 2.5 [1.3-4.7]), and this observation was similar among the three categories of risk. In the subsequent period, there was a trend towards a higher rate in the high-risk group (2.07%, 1.4%/year) than in the lowrisk group (0.6%, 0.6%/year). During the first 3 months of treatment the incidence of bleeding was not different between those who received VKAs and those who received DOACs (2.9%/year and 3.3%/year, respectively); after the first 3 months the incidence was 1.4%/year in patients treated with VKAs and 0.5%/year in those receiving DOACs (RR 2.8 [0.7-24.5]).
The receiver operating characteristic (ROC) curve of the ACCP score (Fig. 2) for the prediction of hemorrhagic complications during anticoagulant treatment had poor predictive value (AUC = 0.56 [95% CI, 0.48-0.64]). As shown in the calibration plot (Fig. 3) , the model performed fairly well for low-scoring patients (first to third deciles) but overestimated the probability of bleeding for high-scoring patients.
Discussion
The present study aimed to assess the ability of the ACCP risk score [3] to predict the bleeding occurrence in an inception cohort of patients who started anticoagulant treatment with VKAs or DOACs for acute VTE, and were prospectively followed-up during treatment. According to the ACCP score, more than half of our study patients, equally distributed among patients with unprovoked or provoked index events, would have been classified as being at high risk of bleeding and, therefore, would have been excluded from extended anticoagulation. Indeed, by attributing two points to patients aged > 75 years, the score virtually excludes this important subgroup of patients (almost 30% of our cohort of patients) from long-term treatment. Of interest, in our study, being elderly (either > 65 or > 75 years) was eventually found to be a risk factor for bleeding, together with previous bleeding, severe renal insufficiency and poor anticoagulant control. Mortality was found to be markedly higher in the high-risk group (9.8%) than in the other categories (0.4%), a finding that is apparently attributable to the high incidence in that category of very elderly patients, with concomitant presence of clinically severe conditions. In striking contrast to the ACCP recommendation, a significantly higher proportion of patients in our cohort categorized as at high risk, irrespective of the provoked or unprovoked nature of the index event, received extended anticoagulation (> 1 year) (55.3%; P = 0.0001) compared with patients at low or moderate risk (around 40% in each group). This finding Table 2 The American College of Chest Physicians (ACCP) risk factors and their incidence in the study population; number (%) of bleeding events occurring in the patients with the risk factor; univariate and multivariate hazard ratio (HR) for bleeding of the five risk factors significant at univariate analysis CI, confidence interval; CrCl, creatinine clearance; MB, major bleeding; TIA, transient ischemic attack; TTR, percentage of time spent within the therapeutic range. *Data obtained from the 1522 patients treated with VKA in whom 40 bleeding events were recorded. †Comorbidity included: coronary artery disease/peripheral artery disease, COPD, chronic obstructive pulmonary disease.
suggests that most Italian clinical professionals do not comply with the ACCP recommendations and give extended anticoagulation to a substantial proportion of their patients who would be considered at high risk of bleeding according to the ACCP score. During the 3130 years of follow-up, significantly more bleeding events occurred in the high-risk group (31 events) than in the low-risk group (six events) (P = 0.05). The rate of bleeding was the same during the first 90 days of therapy (3.0%/year) in both the high-risk and low/ moderate-risk categories. These findings support the recommendation to treat with anticoagulants all patients with acute VTE for not less than 3 months, even if they are at high risk of bleeding. After this initial period, the rate of bleeding decreased in both risk categories, although in a more pronounced way in the low/moderaterisk category than in the high-risk category (0.9%/year vs. 1.4%/year, respectively; not significant difference).
It should be pointed out, however, that in patients in our cohort with unprovoked VTE who belonged to the high-risk category of bleeding, the rate of bleeding events occurring after the first 3 months of treatment was rather low (1.4%; 1.6%/year); this rate is much lower than that expected according to the ACCP score in this category of risk (≥ 6.5%/year). If these results can be confirmed by other real-life studies, the balance between protection against VTE recurrence and risk of bleeding in this type of patients can be set in favor of extended anticoagulation.
Because of the limited number of patients treated with DOACs, and the high risk of incomparability of patients using DOACs or VKAs for 'confounding by indication' [18] we did not analyze the bleeding risk in each of the three classes of risk in these patients, and also did not compare the risk of bleeding in patients treated with VKAs or DOACs. The finding of a relatively high risk of bleeding during extended anticoagulation with VKAs needs to be interpreted cautiously but is in line with other recent data. Caution is necessary because the proportion of patients at high risk of bleeding in the VKA group was much higher than in the DOAC group. Indeed, high major bleeding rates (2.3%/year) in VKA patients were also found in the DULCIS study in those patients who, after standard initial treatment, resumed VKA anticoagulation because of a positive D-dimer assay [19] . The phase III clinical trials on the use of DOACs for extended treatment of VTE patients showed a lower incidence of bleeding compared with warfarin [20, 21] , and very low rates when compared with placebo [22, 23] . It is therefore likely that use of DOACs for extended anticoagulation may be associated with a lower risk of bleeding than VKAs. It should be noted that the ACCP score was designed by analyzing studies based on VKA use only; therefore, any attempt to use this score for assessing the bleeding risk occurring during extended DOAC treatment is questionable.
The main limitation of this study is the relatively small number of patients included, especially of those treated with DOACs. Owing to this, we were not able to formally evaluate which predictor may be a suitable candidate for a predictive rule. All patients, however, were prospectively monitored in a very accurate way and for rather a long time. Another potential limitation is that most of the centers participating in the Register are affiliated with Italian Federation of Anticoagulation Clinics; they represent about 15% of all the centers affiliated with the Federation, which, in turn, provides management of anticoagulation for roughly only 30% of VKA-treated patients in Italy. It is clear, therefore, that the results of the high-performance level in the management of anticoagulated patients of the centers participating in this study cannot be automatically extended to the whole real life of our country. Finally, we were not able to test if biochemical markers (such as GDF-15 or cTNT-hs) could have any additional value over clinical predictors, as recently proposed [24] .
In conclusion, our study found that, according to the bleeding prediction rule and score proposed by the ACCP guideline, more than 50% of all patients managed by some Italian anticoagulation clinics for an acute VTE were categorized as at high risk of bleeding and, therefore, had a contraindication to extended anticoagulation according to the recommendation issued by this guideline; nevertheless, the majority of them received extended anticoagulant treatment. Altogether, the rate of bleeding outcomes during extended treatment was rather low in our cohort of patients. We share the opinion of recent authors [25] [26] [27] that, like other proposed clinical prediction tools, the ACCP score also has very limited predictive value for bleeding occurrence and can hardly be used to guide decisions about suggesting or excluding an extended treatment for the prevention of recurrences in patients with unprovoked VTE. We believe that a better management of VKA anticoagulation and, above all, the fast uptake of DOAC use may change the landscape of anticoagulation-associated risk of bleeding during treatment in VTE patients. New prediction tools for risk of bleeding, updated in relation to the contemporary available therapeutic instruments, are required, as well as new rules for long-term treatment of VTE patients.
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